Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study
暂无分享,去创建一个
David H. Miller | D. MacManus | L. Kappos | C. Polman | K. Schmierer | T. Yousry | M. Dufek | R. Gold | E. Havrdová | Minhua Yang | K. Dawson | V. Limmroth | M. Eraksoy | E. Meluzínová | G. O'neill | David H. Miller
[1] D. MacManus,et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis , 2011, Journal of Neurology.
[2] Ludwig Kappos,et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.
[3] Ludwig Kappos,et al. The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study , 2008 .
[4] James Haorah,et al. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood–brain barrier dysfunction , 2007, Journal of neurochemistry.
[5] P. Hjelmström,et al. Increased CD8+ central memory T cells in patients with multiple sclerosis , 2007, Multiple sclerosis.
[6] W. Hauswirth,et al. Mitochondrial Protein Nitration Primes Neurodegeneration in Experimental Autoimmune Encephalomyelitis* , 2006, Journal of Biological Chemistry.
[7] H. Przuntek,et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot study , 2006, European journal of neurology.
[8] A. Wierinckx,et al. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells , 2005, Journal of Neuroimmunology.
[9] Menotti Calvani,et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: Involvement of the transcription factor Nrf2 , 2005, Journal of neuroscience research.
[10] P. Adeleine,et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.
[11] David H. Miller,et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.
[12] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[13] A. Thompson,et al. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results , 2001, Multiple sclerosis.
[14] T. Scott,et al. Short-term prognosis in early relapsing-remitting multiple sclerosis , 2000, Neurology.
[15] T. Dawson,et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[16] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[17] George Perry,et al. Oxidative stress and neurotoxicity. , 2008, Chemical research in toxicology.
[18] B. Weinshenker,et al. Multiple sclerosis. , 2000, The New England journal of medicine.